3KY Stock Overview
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Hansoh Pharmaceutical Group Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.00 |
| 52 Week High | HK$2.66 |
| 52 Week Low | HK$1.32 |
| Beta | 0.65 |
| 11 Month Change | -22.48% |
| 3 Month Change | -4.76% |
| 1 Year Change | 21.95% |
| 33 Year Change | 4.71% |
| 5 Year Change | -29.08% |
| Change since IPO | 6.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3KY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -6.1% | -0.2% |
| 1Y | 22.0% | -22.4% | 7.8% |
Return vs Industry: 3KY exceeded the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: 3KY exceeded the German Market which returned 7.9% over the past year.
Price Volatility
| 3KY volatility | |
|---|---|
| 3KY Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3KY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3KY's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 9,099 | Huijuan Zhong | www.hspharm.com |
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors.
Hansoh Pharmaceutical Group Company Limited Fundamentals Summary
| 3KY fundamental statistics | |
|---|---|
| Market cap | €12.35b |
| Earnings (TTM) | €614.59m |
| Revenue (TTM) | €1.58b |
20.1x
P/E Ratio7.8x
P/S RatioIs 3KY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3KY income statement (TTM) | |
|---|---|
| Revenue | CN¥12.10b |
| Cost of Revenue | CN¥1.09b |
| Gross Profit | CN¥11.01b |
| Other Expenses | CN¥6.30b |
| Earnings | CN¥4.71b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 91.01% |
| Net Profit Margin | 38.97% |
| Debt/Equity Ratio | 0.1% |
How did 3KY perform over the long term?
See historical performance and comparison